AbbVie Suggests Humira Will Retain Leading Position In 2023

Ahead Of US Biosimilar Competition On Adalimumab Kicking Off Later This Month

 
• By Dave Wallace

AbbVie CEO Richard Gonzalez has set out his expectations for Humira in 2023, with the US market on the cusp of biosimilar competition from multiple adalimumab rivals.

Formation of paper planes with a single red plane leading
AbbVie expects Humira to retain a leading position this year • Source: Shutterstock

More from Biosimilars

More from Products